Roles for miRNAs in endocrine resistance in breast cancer.
Roles for miRNAs in endocrine resistance in breast cancer.
复制标题
DOI：
10.1530/erc-15-0355
复制
发表时间：
2015-10
影响因子：
3.9
通讯作者：
Klinge CM
中科院分区：
文献类型：
--
作者：
Muluhngwi P;Klinge CM
针对雌激素受体α(ERα)的疗法，包括选择性雌激素受体调节剂(SERM)，例如他莫昔芬；选择性雌激素受体下调调节剂(SERD)，即Fulvestrant(ICI182,780)；以及芳香化酶抑制剂(AI)，例如来曲唑，已成功用于治疗初始肿瘤表达ERα的乳腺癌患者。不幸的是，内分泌治疗的有效性受到后天抵抗力的限制。MiRNAs在内分泌耐药乳腺癌进展中的作用在开发生物标记物和治疗转移性疾病方面引起了极大的兴趣。这篇综述集中在miRNAs作为抗雌激素治疗的干扰物，它们真正的基因靶点，以及促进内分泌耐药的相关途径。
Therapies targeting estrogen receptor α (ERα) including selective estrogen receptor modulators (SERMs), e.g., tamoxifen; selective estrogen receptor downregulators (SERDs), i.e., fulvestrant (ICI 182,780); and aromatase inhibitors (AI), e.g., letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ERα. Unfortunately, the effectiveness of endocrine therapies is limited by acquired resistance. The role of miRNAs in the progression of endocrine-resistant breast cancer is of keen interest in developing biomarkers and therapies to counter metastatic disease. This review focuses on miRNAs implicated as disruptors of antiestrogen therapies, their bona fide gene targets, and associated pathways promoting endocrine resistance.